Top Markets
Coin of the day
TAUNS Laboratories, Inc. TAUNS Laboratories, Inc.

TAUNS Laboratories, Inc.

197A
Rank in Stocks #15439
TAUNS Laboratories, Inc. is a company dedicated to the creation and production... TAUNS Laboratories, Inc. is a company dedicated to the creation and production of in-vitro diagnostic pharmaceuticals and various types of measuring equipment. Additionally, the firm facilitates the international trade (import and export) of an extensive selection of instruments, covering industrial, medical, physical, and chemical measurement applications. Founded in April 1987, the company maintains its principal office in Izunokuni, Japan.
Share Price
$3.31
Market Cap
$352.14M
Change (1 day)
0.20%
Change (1 year)
-15.79%
Country
JP
Trade TAUNS Laboratories, Inc. (197A)

Category

P/E ratio for TAUNS Laboratories, Inc. (197A)
P/E ratio as of 2026 TTM: 0
According to TAUNS Laboratories, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for TAUNS Laboratories, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.